[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100503336":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":13,"responsibleParty":42,"collaborators":7,"id":46,"slug":7,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":7,"enrollmentInfo":55,"targetDuration":58,"studyType":59,"phases":7,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":35,"whyStopped":7,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Dongzhimen Hospital, Beijing","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Suhexiang Pill","Suhexiang Pill is an approved traditional Chinese patent medicine.",[14,34],{"facility":15,"status":16,"city":17,"state":18,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"Dongzhimen Hospital","NOT_YET_RECRUITING","Beijing","Beijing Municipality","100700","China","CN",{"type":23,"coordinates":24},"Point",[25,26],116.39723,39.9075,{"lat":26,"lon":25},[29],{"name":30,"role":31,"phone":32,"phoneExt":7,"email":33},"Xinxing Lai, M.D.","CONTACT","15901111280","new-star@163.com",{"facility":15,"status":35,"city":17,"state":18,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":36,"geoPoint":38,"contacts":39},"RECRUITING",{"type":23,"coordinates":37},[25,26],{"lat":26,"lon":25},[40],{"name":30,"role":31,"phone":41,"phoneExt":7,"email":33},"08615901111280",{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Ying Gao","Professor","100503336",false,"NCT05833932","Suhexiang Pill for Acute Ischemic Stroke: A Registry Study","Suhexiang Pill for Acute Ischemic Stroke: A Prospective Registry Study of Real-world Data","SUNRISE","Inclusion Criteria:\n\n* Acute ischemic stroke within 7 days of symptom onset.\n* Age ≥ 18\n* Patient who has received Suhexiang Pill treatment\n* Patient or legally authorized representative has signed informed consent.\n\nExclusion Criteria:\n\n* Be allergic to Suhexiang Pill\n* Known to be pregnant or breastfeeding.\n* With conditions that render outcomes or follow-up unlikely to be assessed.","ALL","18 Years",{"count":56,"type":57},1000,"ESTIMATED","1 Year","OBSERVATIONAL","The primary purpose of this study is to investigate the effectiveness and safety of the Suhexiang Pill for patients with acute ischemic stroke in real-world settings.",[62],"Ischemic Stroke",[64,65,66],"acute ischemic stroke","traditional Chinese medicine","registry study","2024-06-10",{"date":69,"type":70},"2024-06-11","ACTUAL",{"date":72,"type":70},"2023-06-01",{"date":74,"type":57},"2024-12-31",{"name":5,"class":6},2]